TQB-2858 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase II drugs for Nasopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TQB-2858 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TQB-2858 overview

TQB-2858 is under development for the treatment of advanced malignant solid tumors, recurrent or metastatic advanced alveolar soft tissue sarcoma, pleomorphic sarcoma, classic osteosarcoma, Ewing sarcoma, chondrosarcoma, dedifferentiated liposarcoma, cervical cancer and hematological tumors and recurrent/metastatic nasopharyngeal cancer. It is administered through intravenous drip. It acts by targeting PDL1 and transforming growth factor beta (TGFb).

It was also under development for the treatment of endometrial cancer, advanced metastatic pancreatic cancer.

Chia Tai Tianqing Pharmaceutical Group overview

Chia Tai Tianqing Pharmaceutical Group (CTTQ) manufactures and commercializes anticancer drugs. The company produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, engineering novel liver, cardiovascular, cancer, mental, anesthesia, urinary, and others. The company operates through its technology and research and development centers in Jiangsu. CTTQ is headquartered in Lianyungang, Nanjing, China.

For a complete picture of TQB-2858’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 January 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.